Lisinopril vs Carvedilol for Trastuzumab Cardiotoxicity in Breast Cancer
15 Jan 2022
Contributed by Lukas
Preventing the cardiotoxicity of Trastuzumab
Acute vs Subacute Coronary Angiography in NSTEMI
15 Jan 2022
Contributed by Lukas
The findings of NONSTEMI Trial
Peri-operative beta-blockers in non-cardiac surgery
15 Jan 2022
Contributed by Lukas
The findings of Cochrane database systematic review
Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy
15 Jan 2022
Contributed by Lukas
The findings of STICH trial
OAC Monotherapy in Patients with Stable CAD and Non-valvular AF
15 Jan 2022
Contributed by Lukas
OACs in Stable CAD and AF
Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI
15 Jan 2022
Contributed by Lukas
P2Y12 loading dose timing in PCI
Pantoprazole in Patients Receiving Rivaroxaban and/or Aspirin
15 Jan 2022
Contributed by Lukas
The findings of COMPASS trial
Risk of Mortality Following Catheter Ablation of AF
15 Jan 2022
Contributed by Lukas
Mortality risk after AF ablation
Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease
15 Jan 2022
Contributed by Lukas
The findings of EXCEL Trial
Restarting Antiplatelet After ICH Cuts Recurrence Risk in Half
15 Jan 2022
Contributed by Lukas
The findings of REASTART Trial
Bedtime hypertension treatment improves cardiovascular risk reduction
15 Jan 2022
Contributed by Lukas
The findings of Hygia Chronotherapy Trial
Ezetimibe for the prevention of heart disease and death
15 Jan 2022
Contributed by Lukas
The role of Ezetimibe in reducing CVD adverse outcomes
Anticoagulation in HF and sinus rhythm
15 Jan 2022
Contributed by Lukas
OACs in HF and sinus rhythm
TAVR vs SAVR: insights from ACC.19
15 Jan 2022
Contributed by Lukas
The findings of PARTNER 3 and EVOLUT trials
Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or TIA
15 Jan 2022
Contributed by Lukas
DAPT after ischemic stroke or TIA
Antithrombotic Therapy after ACS or PCI in AF
15 Jan 2022
Contributed by Lukas
The findings of AUGUSTUS Trial
Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis
15 Jan 2022
Contributed by Lukas
Stenting vs endarterectomy in symptomatic carotid stenosis
Canagliflozin and Renal Outcomes in T2Dm and Nephropathy
15 Jan 2022
Contributed by Lukas
The findings of CREDENCE Trial
Hypertension and Hyperlipidemia Academy: 4th session
14 Jan 2022
Contributed by Lukas
H&H Academy session 4
Ticagrelor Hub: when to use and which dose?
14 Jan 2022
Contributed by Lukas
The dosage and indications of Ticagrelor
Management of dyslipidemia in diabetic patients
14 Jan 2022
Contributed by Lukas
DLP and T2DM: approach and management
Umbrella Heart and Stroke: session 1, detecting & managing patients with PFO
14 Jan 2022
Contributed by Lukas
Umbrella H&S: session1, PFO
Primary prevention in dyslipidemia as the only cardiovascular risk factor
14 Jan 2022
Contributed by Lukas
Dyslipidemia in primary prevention of low-risk patients
Late-breaking Science in Cardiovascular disease prevention
14 Jan 2022
Contributed by Lukas
ESC 2021 cardiovascular prevention guideline lectures and discussion
DiaBeat: The Beating Heart of Diabetes (8th session)
14 Jan 2022
Contributed by Lukas
8th Diabetes Masterclass for Cardiologists
Cardiometabolic Grand Round (5)
14 Jan 2022
Contributed by Lukas
The 5th session of Cardiometabolic grand round
An introduction to a new series; HeartCast
14 Jan 2022
Contributed by Lukas
HeartCast introduction
The clinical landscape for Diabetes and Cardiovascular disease
14 Jan 2022
Contributed by Lukas
T2DM and cardiovascular diseases: The clinical landscape
Hypertension and Hyperlipidemia Academy 5, a hybrid event
14 Jan 2022
Contributed by Lukas
5th session of H&H Academy, online and onsite
DiaBeat: The Beating Heart of Diabetes (6th session)
14 Jan 2022
Contributed by Lukas
6th Diabetes Masterclass for Cardiologists
Symptom matters: angina control in coronary artery disease
14 Jan 2022
Contributed by Lukas
From surrogates to symptom control in CAD
Marking the antiplatelet therapy maze in ACS
14 Jan 2022
Contributed by Lukas
How to prevent atherosclerotic cardiovascular events
DiaBeat: The Beating Heart of Diabetes (7th session), a scientific debate
14 Jan 2022
Contributed by Lukas
7th Diabetes Masterclass for Cardiologists
Antithrombotic lighthouse, Cases and Faces: antithrombotic therapy in CAD
14 Jan 2022
Contributed by Lukas
Antithrombotic regimens in CAD
From optimal medical therapy to revascularization in CCS
14 Jan 2022
Contributed by Lukas
Choosing the best therapeutic strategy in CCS
Cardiovascular complications of T2DM: the preventive role of SGLT2Is
14 Jan 2022
Contributed by Lukas
SGLT2Is and the prevention of cardiovascular complications in T2DM
Cardiometabolic Grand Round (4)
14 Jan 2022
Contributed by Lukas
Guideline-directed cardiovascular evaluations before surgery
Tailored Antithrombotic therapy for CCS patients
14 Jan 2022
Contributed by Lukas
Best individual antithrombotic strategy in CCS
DCS 1400: session 8, Valvular Heart disease
14 Jan 2022
Contributed by Lukas
The eighth panel of DCS 1400: Valvular Heart disease
The evolution of antiplatelet therapy in CAD: a 45 year journey
14 Jan 2022
Contributed by Lukas
A brief history of anti-platelet therapy in CAD
Dual antiplatelet therapy in2021: Current recommendations
14 Jan 2022
Contributed by Lukas
The latest updates on DAPT
How to reduce the atherosclerotic cardiovascular risk
14 Jan 2022
Contributed by Lukas
A case-based Review on HTN and DLP management
DiaBeat: The Beating Heart of Diabetes (1st session)
14 Jan 2022
Contributed by Lukas
1st Diabetes Masterclass for Cardiologists
PCSK9 inhibitors place in patients with cardiometabolic diseases
14 Jan 2022
Contributed by Lukas
PCSK9 inhibitors from two perspectives of Endocrinologist & Cardiologist
Residents’ Island: Abidi CVD Prevention Academy
14 Jan 2022
Contributed by Lukas
Multidisciplinary approach to CVD Prevention
Cardiometabolic Grand Round (3)
13 Jan 2022
Contributed by Lukas
A brief talk on DM medication challenges in patients with CVD
7th Case: Thrombocytopenia
13 Jan 2022
Contributed by Lukas
Any Concerns for OACs Use in Patients with Thrombocytopenia
5th Case: Stable ASCVD
13 Jan 2022
Contributed by Lukas
Low dose Rivaroxaban in SIHD, COMPASS trial
6th Case: Hepatic Impairment
13 Jan 2022
Contributed by Lukas
OAC of choice in patients with hepatic impairment, any difference between DOACs?
8th Case: Intracranial Bleed
13 Jan 2022
Contributed by Lukas
OAC Choice in High Thrombotic Risk Patients after ICH
10th Case: Drug Drug Interactions
13 Jan 2022
Contributed by Lukas
DOACs important interactions in clinical practice
9th Case: Renal Insufficiency
13 Jan 2022
Contributed by Lukas
OAC Management in Patients with CKD
4th Case: Extreme Body Weights
13 Jan 2022
Contributed by Lukas
OAC choice in patients with obesity or low body weights, any role for DOACs?
3rd Case: AF & Artificial Heart Valves
13 Jan 2022
Contributed by Lukas
OAC of choice in patients with artificial heart valves
2nd Case: Cancer associated VTE
13 Jan 2022
Contributed by Lukas
Anticoagulation of choice in patients with cancer, the importance of DDI
1st Case: Elective PCI and AF
13 Jan 2022
Contributed by Lukas
Antithrombotic regimen of choice in patients with AF undergoing elective PCI
SGLT2 inhibition: A snapshot into their evolution
13 Jan 2022
Contributed by Lukas
Endocrinologist Perspective on SGLT2 inhibitors
SGLT2 inhibition: Making waves in the heart failure landscape
12 Jan 2022
Contributed by Lukas
Role of SGLT2 inhibitors in HF patients from two perspectives: Endocrinology & Cardiology
Cardiometabolic Grand Round (2)
12 Jan 2022
Contributed by Lukas
A brief talk on DM medication challenges in patients with CVD
Paradigm Shift in Treating Intermediate Risk Pulmonary Embolism
11 Jan 2022
Contributed by Lukas
Concise Talk on Intermediate Risk Pulmonary Embolism, update by an expert in the field
How to Implement the Newest Diabetes Therapies in HF Treatment
11 Jan 2022
Contributed by Lukas
New insight from EMPEROR Reduced Trial
What we learned from ESC Congress about HTN Management
11 Jan 2022
Contributed by Lukas
A Brief Discussion on HTN Management Pearls of ESC 2020
VTE Prophylaxis in Patients with COVID-19
11 Jan 2022
Contributed by Lukas
Challenges on VTE Prophylaxis in different settings (inpatient, outpatient, upon discharge)
ESC 2020 Congress Coverage What is new on NSTE-ACS Guideline: a panel discussion
11 Jan 2022
Contributed by Lukas
Brief Discussion on the New ESC Guideline on NSTE-ACS
Diabetes and Cardiovascular Diseases
11 Jan 2022
Contributed by Lukas
On the occasion of World Heart Day 2020 for the management of Cardiovascular risk factors
Smoking and the Heart the Struggle Continues
11 Jan 2022
Contributed by Lukas
On the occasion of World Heart Day 2020 for the management of Cardiovascular risk factors
Ground-breaking research from ESC Congress 2020 (23)
11 Jan 2022
Contributed by Lukas
Part Twenty-three: Trial Review, ELDERCARE-AF
Ground-breaking research from ESC Congress 2020 (21)
11 Jan 2022
Contributed by Lukas
Part Twenty-One: Trial Review, BPLTTC (CANCER)
Ground-breaking research from ESC Congress 2020 (22)
11 Jan 2022
Contributed by Lukas
Part Twenty-Two: Trial Review, ATPCI
Ground-breaking research from ESC Congress 2020 (17)
10 Jan 2022
Contributed by Lukas
Part Seventeen: Trial Review, REALITY
Ground-breaking research from ESC Congress 2020 (15)
10 Jan 2022
Contributed by Lukas
Part Fifteen: Trial Review, PARALLAX
Ground-breaking research from ESC Congress 2020 (9)
10 Jan 2022
Contributed by Lukas
Part Nine: Trial Review, RATE-AF
Ground-breaking research from ESC Congress 2020 (11)
10 Jan 2022
Contributed by Lukas
Part Eleven: Trial Review, DAPA-CKD
Ground-breaking research from ESC Congress 2020 (20)
10 Jan 2022
Contributed by Lukas
Part Twenty: Trial Review, POPULAR TAVI
Ground-breaking research from ESC Congress 2020 (14)
10 Jan 2022
Contributed by Lukas
Part Fourteen: Trial Review, POPULAR CABG
Ground-breaking research from ESC Congress 2020 (19)
10 Jan 2022
Contributed by Lukas
Part Nineteen: Trial Review, EXPLORER-HCM
Ground-breaking research from ESC Congress 2020 (18)
10 Jan 2022
Contributed by Lukas
Part Eighteen: Trial Review, HOME-PE
Ground-breaking research from ESC Congress 2020 (4)
10 Jan 2022
Contributed by Lukas
Part Four: Trial Review, BRACE-CORONA
Ground-breaking research from ESC Congress 2020 (16)
10 Jan 2022
Contributed by Lukas
Part Sixteen: Trial Review, BPLTTC
Ground-breaking research from ESC Congress 2020 (12)
10 Jan 2022
Contributed by Lukas
Part Twelve: Trial Review, EVAPORATE
Ground-breaking research from ESC Congress 2020 (3)
10 Jan 2022
Contributed by Lukas
Part Three: Trial Review; THEMIS, PAD
Ground-breaking research from ESC Congress 2020 (1)
10 Jan 2022
Contributed by Lukas
Congress Coverage: Introduction
Ground-breaking research from ESC Congress 2020 (10)
10 Jan 2022
Contributed by Lukas
Part Ten: Trial Review, DECLARE-TIMI
Ground-breaking research from ESC Congress 2020
10 Jan 2022
Contributed by Lukas
Brief Review of Main Trials Discussed in ESC Congress 2020
Ground-breaking research from ESC Congress 2020 (2)
10 Jan 2022
Contributed by Lukas
Part Two: Trial Review, EMPEROR-REDUCED
Ground-breaking research from ESC Congress 2020 (5)
10 Jan 2022
Contributed by Lukas
Part Five: Trial Review, EAST-AFNET4
Ground-breaking research from ESC Congress 2020 (13)
10 Jan 2022
Contributed by Lukas
Part Thirteen: Trial Review, BAMI
Current Cardiology Practice of Antithrombotics in ASCVD: A Case Based Panel Discussion
10 Jan 2022
Contributed by Lukas
Brief discussion on choice of antithrombotic agents in patients with chronic coronary syndrome and p...
Cardiometabolic Care Network
10 Jan 2022
Contributed by Lukas
Interprofessional Collaboration Practice in Risk Management of ASCVD
Shielding the Brain From Stroke
10 Jan 2022
Contributed by Lukas
A case based discussion on optimization of antithrombotic therapy in patients with ischemic stroke
Ground-breaking research from ESC Congress 2020 (7)
10 Jan 2022
Contributed by Lukas
Part Seven: Trial Review, COLCOT
Ground-breaking research from ESC Congress 2020 (8)
10 Jan 2022
Contributed by Lukas
Part Eight: Trial Review, COPS
Ground-breaking research from ESC Congress 2020 (6)
10 Jan 2022
Contributed by Lukas
Part Six: Trial Review, LoDoCo2
Low-dose Rivaroxaban in Management of PAD Patients
10 Jan 2022
Contributed by Lukas
Insights from COMPASS & VOYAGER Trials
Low-dose Rivaroxaban in Management of Post-Revascularized CAD Patients
10 Jan 2022
Contributed by Lukas
Insights from COMPASS-PCI & COMPASS-CABG Trials
COVID-19 and thrombotic or thromboembolic disease: implication for prevention, antithrombotic therapy, and follow up
10 Jan 2022
Contributed by Lukas
Antithrombotic challenge in patients with COVID-19; focus on JACC State of ART review
Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19)Hydroxychloroquine: A magic bullet?
10 Jan 2022
Contributed by Lukas
The role of medications in the pre and post prophylaxis against COVID-19
COVID and Cardiometabolic Challenges
10 Jan 2022
Contributed by Lukas
Multidisciplinary approach to COVID-19 Cardiometabolic Complications
The evolving pandemic of COVID-19 and invasive cardiology consideration
09 Jan 2022
Contributed by Lukas
Brief description of COVID-19 effect on approaching invasive strategies in patients with CVD
COVID-19 Cath Lab Implications
09 Jan 2022
Contributed by Lukas
A frontline View from Italy